Found: 22
Select item for more details and to access through your institution.
Second cancers in MPN: Survival analysis from an international study.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 3, p. 295, doi. 10.1002/ajh.25700
- By:
- Publication type:
- Article
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 3, p. 318, doi. 10.1002/ajh.24269
- By:
- Publication type:
- Article
Minimal residual disease as biomarker for optimal biologic dosing of ARA- C in patients with acute myeloid leukemia.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 2, p. 125, doi. 10.1002/ajh.23893
- By:
- Publication type:
- Article
Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting.
- Published in:
- European Journal of Haematology, 2023, v. 111, n. 2, p. 311, doi. 10.1111/ejh.14012
- By:
- Publication type:
- Article
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1‐negative Myeloproliferative Neoplasms Latium Group".
- Published in:
- European Journal of Haematology, 2020, v. 105, n. 3, p. 335, doi. 10.1111/ejh.13454
- By:
- Publication type:
- Article
Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant.
- Published in:
- Transfusion, 2010, v. 50, n. 2, p. 501, doi. 10.1111/j.1537-2995.2009.02439.x
- By:
- Publication type:
- Article
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00724-3
- By:
- Publication type:
- Article
Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene.
- Published in:
- 2010
- By:
- Publication type:
- Letter
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 6, p. 1233, doi. 10.1002/cam4.1081
- By:
- Publication type:
- Article
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
- Published in:
- European Journal of Haematology, 2016, v. 96, n. 6, p. 643, doi. 10.1111/ejh.12674
- By:
- Publication type:
- Article
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 2, p. 190, doi. 10.1111/bjh.18057
- By:
- Publication type:
- Article
Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 4, p. e100, doi. 10.1111/bjh.15931
- By:
- Publication type:
- Article
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.
- Published in:
- Leukemia Research & Treatment, 2013, p. 1, doi. 10.1155/2013/705714
- By:
- Publication type:
- Article
Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: A retrospective analysis of 116 HIV-positive and HIV-negative immunocompromised patients.
- Published in:
- PLoS ONE, 2017, v. 12, n. 5, p. 1, doi. 10.1371/journal.pone.0176881
- By:
- Publication type:
- Article
Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience.
- Published in:
- Cancers, 2022, v. 14, n. 19, p. 4897, doi. 10.3390/cancers14194897
- By:
- Publication type:
- Article
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.
- Published in:
- Cancers, 2019, v. 11, n. 9, p. 1373, doi. 10.3390/cancers11091373
- By:
- Publication type:
- Article
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 9, p. 2596, doi. 10.3390/jcm11092596
- By:
- Publication type:
- Article
Recurrence of a t(8;21)-Positive Acute Myeloid Leukemia in the Form of a Granulocytic Sarcoma Involving Cranial Bones: A Diagnostic and Therapeutic Challenge.
- Published in:
- Case Reports in Hematology, 2013, p. 1, doi. 10.1155/2013/245395
- By:
- Publication type:
- Article
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 6, p. 1275, doi. 10.1007/s00277-022-04815-w
- By:
- Publication type:
- Article
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Extensive toxic epidermal necrolysis following brentuximab vedotin administration.
- Published in:
- 2015
- By:
- Publication type:
- Letter